Close Menu

colorectal cancer

BioArray Briefs: 2009.02.17

Premium

SQI Diagnostics, Olink Bioscience, Innova Biosciences, Copenhagen University, Fujirebio Diagnostics, Uppsala University, Integromics, Gene Logic, Ocimum Biosolutions

The three-year project, called Proactive, will be coordinated by Olink Bioscience of Uppsala, Sweden.

The data, which the company said represent the first proof of activity of an oral RNAi drug, set the stage for an investigational new drug application filing later this year.

IP Update

Premium

USPTO Publishes Seven RNAi-Related Patent Applications

Without specific guidance from the FDA regarding KRAS testing, drugmakers Bristol-Myers Squibb and Amgen are facing lower sales of their colorectal cancer drugs Erbitux and Vectibix, and may need to get creative in how they market their drugs to patients and doctors.

New Product Watch

Premium

Navigenics, ImaGenes, Ocimum Biosolutions

While Helicos and Rosetta Genomics rose, shares of Cepheid were hit by its forecast of lower revenues. But, overall, the GWDN Index managed to gain ground while the broader market fell.

Pages

Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.

University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.

The Wall Street Journal examines billing codes used by uBiome.

In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.